Definite causes for several pathologies of pregnancy remain unknown. In light of several recent studies, however, diminished or aberrant HLA-G expression may be associated with certain complication of pregnancy and be linked to HLA-G polymorphism. We analyzed DNA from 60 normal placentas (controls), 140 placentas from miscarriage, 36 placentas from preeclampsia, 76 placentas from fetal hypotrophy, and 34 placentas with hypoxia for variations in coding regions (allelic groups G*0101 to G*0107) and the 14-bp deletion/insertion into the 3 0 -untranslated region. No statistically significant differences were observed in the distribution of allelic group between pathological placentas and controls with the exception of G*0106 allele frequency in preeclamptic compared with control placentas (21.2% and 6.6%, respectively). A greater frequency of this allele also was observed in the two subgroups of miscarriage and hypoxia compared with that in controls. In addition, presence of the 14-bp sequence was prominent in preeclampsia compared with controls (60.8% vs. 35%, respectively), and homozygotes with deletion were not detected in the pathology. The results suggest that the G*0106 allele, which is coupled with the presence of the 14-bp sequence, contributes and/or is a relevant marker in some specific complications of pregnancy, especially preeclampsia.
INTRODUCTION
Pregnancy is a homeostatic state whereby the maternal immune system is in close contact with semiallogeneic fetal tissues. Considering that the fetus can survive despite the maternal immune system, pregnancy thus seems to be an immunological paradox. Nonetheless, complications of pregnancy may occur, such as preeclampsia (PE) and miscarriage, which involve mechanisms that are incompletely understood at present. An important issue is HLA-G, a nonclassical, HLA class I molecule with immunosuppressive properties [1] first evidenced at the fetal-maternal interface at the cell surface of invasive cytotrophoblasts [2, 3] . Data have been accumulated showing that HLA-G is an important factor in modulation of the maternal immune system during pregnancy and, thereby, in complications of pregnancy [4] .
In preimplantation embryos, HLA-G is expressed very early during pregnancy [5, 6] , and most recent studies have shown that human embryos in culture secrete soluble forms of HLA-G into the culture medium and that secretion patterns are positively associated with their implantation outcome [7] [8] [9] [10] [11] [12] . Apart from pregnancy, HLA-G protein expression in nonpathological tissues is restricted to thymus [13, 14] , cornea [15] , proximal nail matrix [16] , and pancreas [17] . In addition, HLA-G is secreted by hematopoietic cells in all organs sustaining erythropoiesis [18] . Conversely, ectopic HLA-G expression is observed under pathological situations, such as tumor lesion [19] , inflammation and autoimmune diseases [20, 21] , viral infection [22] , and grafted organs [23] . The HLA-G exerts its inhibitory functions on cell cytotoxicity [24] [25] [26] [27] and alloproliferative responses [28] [29] [30] [31] through interaction with at least three inhibitory receptors present on natural killer, T, and antigen-presenting cells-namely, LILRB1 (leukocyte immunoglobulin-like receptor, subfamily B, with TM and ITIM domains, member 1; ILT-2/CD85j), LILRB2 (leukocyte immunoglobulin-like receptor, subfamily B, with TM and ITIM domains, member 2; ILT-4/CD85d), and KIR2DL4 (killer cell immunoglobulin-like receptor, two domains, long cytoplasmic tail, 4; CD158d) [32] [33] [34] [35] [36] [37] . Recently, we also demonstrated that trogocytosis of HLA-G could be a major mechanism of immune escape that acts through effector cells made to act locally as suppressor cells [38] .
The HLA-G exhibits seven isoforms, four membrane-bound forms (HLA-G1 to HLA-G4) and three soluble forms (HLA-G5 to HLA-G7), that are generated by an alternative splicing of primary transcript [1] . Polymorphism of HLA-G protein is reduced, with only 10 different proteins encoded by 30 alleles having a majority of conserved substitutions in the coding sequence (http://www.anthonynolan.com/HIG/seq/refs/gref. html). In addition, one modified protein can be generated by G*0105N ''null'' allele because of a frameshift in exon 3 that generates a premature stop codon in exon 4 or 5, depending on the alternative splicing [39, 40] . The 31 alleles of HLA-G are defined by polymorphism not only in the coding region but also in the noncoding region. These variations have been identified in introns, in the promoter gene region with at least 27 SNPs and 13 combinations [41] , and in the 3 0 -untranslated region (UTR) with a 14-bp deletion/insertion (À/þ) polymorphism [42] and a C/G SNP (single nucleotide polymorphism) at position þ3142 [43] . Interestingly, most of the polymorphisms found in the promoter region are located in regulatory regions and, thus, might affect gene expression [41, 44] . The presence of the 14-bp sequence in the 3 0 -UTR was associated with significantly reduced HLA-G mRNA levels [45, 46] and no detectable soluble HLA-G in serum [47] . This makes alleles such as G*0106, G*0103, G*010102, G*010103, and G*0105N, low-secretor candidates for soluble HLA-G [46, 48] . In addition, the 14-bp sequence generates an additional splice whereby 92 bases are removed from the start of exon 8 in HLA-G transcripts [49] . Such a deletion generates an HLA-G mRNA subpopulation that is more stable than those having the complete ''exon 8'' [50] . Moreover þ3142 C/G in the 3 0 -UTR of the HLA-G gene recently was demonstrated to influence the targeting of three microRNAs to the HLA-G mRNA [43] .
Recent data indicate that HLA-G polymorphism may influence the clinical response to methotrexate treatment in rheumatoid arthritis [51] . In addition, HLA-G polymorphism has been linked to pathological situations, such as pemphigus vulgaris [52] , inflammatory bowel disease [53] , sarcoidosis [54] , and idiopathic dilated cardiomyopathy [55] . The overall picture emerging from different independent studies is that some HLA-G polymorphism also is associated with complications of pregnancy, such as implantation failure during in vitro fertilization (IVF) [47] , recurrent spontaneous abortion (RSA) [56] [57] [58] [59] [60] [61] , and PE [45, 62, 63] . Nonetheless, some of these associations are controversial.
The aim of the present study was to investigate further the association between HLA-G gene polymorphism and several diseases of pregnancy, including PE, miscarriage, placental hypoxia (HY), and fetal hypotrophy (FH), focusing on placentas. Two HLA-G gene polymorphisms were investigated: One corresponded to variations in coding regions that define 11 allelic groups (G*0101 to G*0111), four of which (G*0108 [64] to G*0111) have been very recently identified and were not included in the present analysis; the other one corresponded to the 14-bp À/þ polymorphism into the 3 0 -UTR of the HLA-G gene. We found that the G*0106 allele and the presence of the 14-bp sequence in the 3 0 -UTR in the fetus would be useful markers in some pregnancy complications.
MATERIALS AND METHODS

Placenta Samples and DNA Isolation
Sixty normal placentas (controls), 140 placentas from miscarriage (36 having recurrent cytotrophoblasts and 17 with invaginated cysts), 36 PE placentas, 76 FH placentas, and 34 placentas with HY were obtained from patients at private hospitals in Bordeaux (France). Informed consent was obtained from all patients, and the investigations were approved by the local ethical committee of the Saint-Louis Hospital of Paris (France). Pregnancies complicated by PE were diagnosed by at least two of the following features: elevated blood pressure, edema, and proteinuria. The diagnosis of FH was based on Doppler studies, fetal morphometry, and the absence of additional clinical parameters. The diagnosis of HY was based on placenta morphometry and patterns of fetal capillary angiogenesis. Pregnancy outcome was heterogeneous in the FH cohort (Table 1) . When necessary, diagnoses of pathologies were validated by microscopy at the Institut d'Histo-CytoPathologie in Le Bouscat (France).
Pieces of amnion and/or villi were snap-frozen in liquid nitrogen and stored at À808C until required for isolation of genomic DNA. Genomic DNA was prepared from tissue samples using standard techniques as described previously [45] .
HLA-G Allele Typing
Genotyping of HLA-G alleles was performed by PCR-SSP (sequence specific primer). Only HLA-G alleles specifically coding for nonconservative amino acid substitutions were determined. The 11 primer mixes used for HLA-G typing allowed us to detect seven HLA-G alleles, as shown in Table 2 .
The PCR reaction mixtures (10 ll) contained 100 ng of genomic DNA; PCR buffer (50 mM KCl, 1.5 mM MgCl 2 , 10 mM Tris-HCl [pH 8.3] , and 0.001% [w/v] gelatin); 200 lM each of dATP, dCTP, dGTP, and dTTP; 1 lM of the sequence-specific primers; 0.5 lM control primers; and 0.25 U of AmpliTaq (Sigma Bioscience) diluted 1:10 in 13 PCR buffer. Amplification was carried out with a GenAmp PCR system 9700 (Applied Biosystems) for 10 cycles at two different temperatures (10 sec at 948C and 60 sec at 658C), followed by 20 cycles at three different temperatures (30 sec of denaturation at 948C, 50 sec of annealing at 618C, and 30 sec of extension at 728C). The amplified products were revealed by 3% agarose gel electrophoresis at 150 V for approximately 10 min.
A specific primer pair for a limited region of the human b-globin gene (present in all DNA samples) was used for positive control of amplification in each PCR reaction. The primers were Beta5 5 0 -GCTGCTATCACTTA-GACCTCA-3 0 and Beta3 5 0 -CTTGTCACAGTGCAGCTCAC-3 0 , which produced a fragment of 592 bp.
The HLA-G allele typing results were validated by DNA samples typed at allele-level resolution during the 10th International Histocompatibility Workshop. Samples positive for G*0106 were confirmed by direct sequencing of exon 4 as described previously [65] . The G*0102 and G*0107 alleles were not found in any of our DNA samples from placentas.
Typing of 14-bp
Genotyping of the HLA-G 14-bp À/þ polymorphism was performed as described previously [58] with minor changes. Briefly, 100 ng of genomic DNA were amplified in a final reaction volume of 25 ll containing 13 PCR buffer; 0.2 mM each of dATP, dCTP, dGTP, and dTTP, 1.5 mM MgCl 2 , 0.75 U of Taq Polymerase (Sigma-Bioscience), and 10 pmol of each primer (GE14HLAG and RHG4). Thermocycling conditions were as follows: initial denaturation at 948C for 2 min; followed by 25 PCR cycles of 948C for 30 sec, 648C for 60 sec, and 728C for 120 sec; and then a final extension at 728C for 10 min.
The amplification products were visualized by electrophoresis on a 2.5% agarose gel (Invitrogen) containing 0.5 ll/ml of ethidium bromide.
Statistical Analysis
The allele and genotype frequencies of two HLA-G polymorphisms (HLA-G*0101 to HLA*G0107 and the 14-bp À/þ polymorphism in the 3 0 -UTR were estimated by direct counting. 
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The allele and genotype frequencies observed in each diseased group were compared with those of the healthy control group by the chi-square test using a 232 contingency table.
All significant chi-square tests were confirmed by the two-tailed Fisher exact test. The P values were corrected for the number of comparisons (n ¼ 7) according to Bonferroni. Only P values of 0.05 or less after Bonferroni correction were regarded as being significant and suggestive of gene marker and disease association.
Odd ratios, with 95% confidence intervals, were calculated according to the Woolf method to measure the strength of disease association with HLA-G alleles and genotypes. The Haldane correction of the Woolf formula was applied when critical entries were zero.
The genotype frequencies observed in the control and diseased groups for HLA-G alleles and the 14-bp À/þ polymorphism in exon 8 were compared to Hardy-Weinberg expectations using a modified version of the Markov chain exact test [66] . This procedure is similar to the Fisher exact test on a 232 contingency table but is extended to a triangular contingency table of arbitrary size. This version gives the same results as the original but is more efficient from a computational viewpoint.
The frequencies of two-locus haplotypes based on HLA-G alleles (locus 1) and the 14-bp À/þ polymorphism in exon 8 (locus 2) were estimated by the maximum likelihood method using the Arlequin program, version 2 (Schneider S., Roessli D., Excoffier L., Switzerland). The haplotype frequencies of the diseased groups were compared with those of the control group by the Fisher exact test.
The linkage disequilibrium for haplotypes of two HLA-G loci was calculated as the difference between the estimated frequency of a given haplotype and the frequency that one would expect by chance alone: DAB ¼ PAB À PA 3 PB; where DAB ¼ linkage disequilibrium of allele A at locus 1 with B at locus 2, PAB ¼ frequency of A at locus 1 with B at locus 2, PA ¼ frequency of A at locus 1, and PB ¼ frequency of B at locus 2.
For comparisons, the magnitude of the observed D (linkage disequilibrium) value was standardized in relation to the maximal possible value when the observed D value was positive or to the minimal value when the observed D value was negative. In the first case, D standard (
RESULTS
Typing of HLA-G Gene Allelic Groups G*0101 to G*0107 in Normal and Pathological Placentas
The results shown in Table 3 were obtained from 60 normal placentas (controls); 113 placentas from miscarriage, with 28 having recurrent cytotrophoblasts (M/rc) and 17 having invaginated cysts (M/cy); 33 PE placentas; 59 FH placentas; and 32 HE placentas, 7 of which were diagnosed as intrauterine growth restriction (HY/IUGR). Placental DNA was analyzed for HLA-G polymorphism in the coding region that defines the G*0101 to G*0107 allelic groups (Table 3) . First, it is noteworthy that alleles belonging to the G*0102 and G*0107 groups were not detected in normal or pathological placentas. Second, the G*0105N allele was found only in two control and six FH placentas. Third, the G*0101, G*0103, G*0104, and G*0106 variants were detected in both normal and pathological placentas. For testing Hardy-Weinberg equilibrium, we analyzed HLA-G genotypes in two groups, normal placentas and all pathological placentas. The HLA-G genotypes were in Hardy-Weinberg equilibrium for the normal group only (data not shown). The allele and genotype frequencies observed in each diseased group were compared with those of the healthy control group (Table 3) . Regarding G*0106 allele frequency, a statistically significant difference was observed in the PE (21.2%, P ¼ 0.0031), M/rc (19.6%, P ¼ 0.0173), and HY/IUGR (28.5%, P ¼ 0.0242) subgroups compared with controls (6.6%). Only the PE subgroup, however, reached significance at P 0.05 after Bonferroni correction. The results of comparisons of genotype frequencies revealed that G*0101/ G*0106 heterozygotes were prominent in the PE (33.3%, P ¼ 0.0024) and M/rc (35.5%, P ¼ 0.0019) subgroups as compared to the control placentas. Significant differences were still observed after Bonferroni correction (P ¼ 0.0168 and 0.0133, respectively). Almost all DNA tested previously for HLA-G gene allelic groups G*0101 to G*0107 also was investigated for the absence or presence of the 14-bp sequence in the 3 0 -UTR. Table 4 presents the results for 60 normal placentas (controls); 135 placentas from miscarriage, 34 having the M/rc phenotype and 15 having the M/cy phenotype; 23 PE placentas; 70 FH placentas; and 34 HY placentas, with 7 having the HY/IUGR phenotype. Focusing on the distribution of the 14-bp À/þ polymorphism, Hardy-Weinberg equilibrium was found only in the control group. When placentas from pregnancy with complications were compared to controls for allele and genotype frequency, a statistically significant difference was only found regarding presence of the 14-bp sequence in the PE subgroup compared with controls (60.8% vs. 35%, respectively; P ¼ 0.0182 after Bonferroni correction). Genotyping analysis revealed a strong association between the 14-bp insertion/deletion HLA-G genotype and the PE subgroup (P ¼ 0.0245 after Bonferroni correction), whereas placentas homo- 462 zygous for absence of the 14-bp sequence were not found in the PE samples (P ¼ 0.0042 after Bonferroni correction).
DISCUSSION
The purpose of the present study was to investigate and/or reexamine the impact of HLA-G gene polymorphism in several complications of pregnancy by analyzing both the allelic families G*0101 to G*0107 and the well characterized, 14-bp À/þ variation in the 3 0 -UTR of the HLA-G gene. First, HLA-G typing of DNAs from 297 placentas did not reveal G*0102 and G*0107 variants. In agreement with this, G*0102 was first reported by Pook et al. [67] and was only identified in a North India female control population with very low frequency (1.2% of 240 chromosomes) [60] . This allele was not detected in African Shona [68] , Danish [4] , and Brazilian [69] populations, however, shedding some doubt on the true existence of this variant [68, 70] . As for G*0107, to date, and to our knowledge, it has been reported in only one study [70] , being found in 1 of 33 cell lines studied, and has not been detected in the Brazilian population [69] .
The distribution of HLA-G polymorphisms has been analyzed previously in several studies, which generally focused on RSA and PE, in which defects in HLA-G expression have been reported [45, [71] [72] [73] . A case-control study demonstrated a significant increased in the proportion of the HLA-G alleles G*01013 (G*010103) and G*0105N in the whole group of women with RSA compared to fertile controls [57] . In agreement with this, a frequent occurrence of G*010103 was found among 120 women with RSA compared to that in 120 normal fertile controls [60] . Another study of 113 couples with unexplained recurrent miscarriage revealed that presence of the G*0104 or G*0105N alleles in either partner was significantly associated with an increase risk for miscarriage [56] ; the possible importance of the G*01013 allele in RSA was not revealed in that study. On the other hand, Hviid et al. [58] genotyped 61 RSA couples and 47 fertile control couples and did not observe any significant differences in the distribution of the above HLA-G alleles. The analysis of variations in the HLA-G gene exons also was addressed regarding PE: A study by Carreiras et al. [74] observed a preferential inheritance of maternal G*0104 alleles among 25 PE mother-child pairs. This result was not observed in a Danish study including 57 family triads (offspring and parents) with PE and 98 control families, in which no obvious differences were observed in the distribution of the HLA-G alleles [62] . In accordance with this, the allelic frequencies of HLA-G alleles in 78 women with PE from a Chinese Han population were not significantly different from those of 146 normal women [75] . Aldrich et al. [76] studied the frequency of the G*0105N allele; however, no discrepancies were found between 57 PE placentas and 36 controls. Although parental genotypes were not analyzed in the present study and, thus, may account for discrepancies between the present results and some of the published data, we did not find any differences in the distribution of G*01013, G*0104, and G*0105N alleles between PE, miscarriage, and control placentas. In particular, the G*0105N allele was observed at a very low frequency in normal placenta and was not detected in placenta from miscarriages and PE. We found a significant difference, however, in G*0106 allelic frequency between normal and PE placentas, and we found this allele more frequently in a subset of miscarriage placentas (M/rc) in comparison with controls. The presence of the G*0106 allele was investigated previously in maternal and paternal samples from PE cases, but those authors did not find any differences between the distribution ASSOCIATION OF HLA-G*0106 WITH PREGNANCY DISEASES of the allele in the PE cases and the controls [65] . Nonetheless, a recent case-control study of 83 Malay women with PE showed that the risk for PE was significantly associated with fetal G*0106 allele in multigravid pregnancies [77] . Interestingly, another study that is in agreement with our results showed more women with RSA carried the G*0106 allele (15%) compared with the fertile control women (2%) [58] . From our genotyping data, it is noteworthy that pathological placentas were heterozygotes. They involved the G*0106 allele and G*0101 family (and, thus, at least one allelic form among the 17 forms that belong to the family). Therefore, despite no significant difference in G*0106 allele frequencies between PE and control parents in the previous study, it seems that allele transmission to the offspring is an informative pathological parameter when associated with other, undefined alleles belonging to the G*0101 family. Accordingly, Tan et al. [77] showed that paternal G*0106 allele contribution significantly increases the risk for PE.
Regarding the 14-bp À/þ polymorphism, controversial results have been reported from studies comparing women with RSA and controls [47, 58, 78] . We analyzed 135 placentas from miscarriage irrespective of recurrent abortion. We observed no significant difference in allelic frequencies, suggesting that presence of the 14-bp sequence in the 3 0 -UTR of the HLA-G gene might not be associated with risk of spontaneous abortion. In fact, it is possible to discern a consensus, both in published data and the present work, regarding the 14-bp À/þ polymorphism and an increased risk of PE associated with overrepresentation of alleles in which 14 bp is present in PE [4] . Nonetheless, genotyping analysis give more divergent results, because either 14-bp insertion/insertion [45, 62] or 14-bp À/þ [79] HLA-G genotypes are associated with PE, depending on the study. Whatever the reasons for these discrepancies, which could be the number of samples included in the study and/or the clinical criteria for selecting samples, we found a significant underrepresentation of the 14-bp deletion/deletion genotype in 
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PE placentas compared with controls, a result observed previously in offspring of primipara with PE [62] .
The present work also analyzed FH and HY placentas. On the one hand, we did not find any association between HLA-G gene variations (exons and 14-bp À/þ polymorphism) and FH, suggesting either that HLA-G is not involved in the observed morphological changes or that more specific determination of allele subfamilies should be made. To our knowledge, only one study has investigated HLA-G polymorphism and clinical parameters of pregnancy, such as birth weight and placenta weight [80] . An HLA-G genotype homozygous for presence of the 14-bp sequence polymorphism was significantly associated with increased birth weight in relation to gestational age and with increased placenta weight at birth compared with the two other genotypes. On the other hand, it is noteworthy that we again found an overrepresentation of the G*0106 allele in HY/ IUGR placentas, although no statistically significant differences were found between this group and controls after Bonferroni correction. Interestingly, the effect of hypoxic environment on the HLA-G expression has been revealed in several cellular models [81] [82] [83] [84] . In turn, HLA-G has been demonstrated to be involved in the regulation of angiogenesis [85, 86] .
Collectively, these results led to the possibility that at least the G*0106 allele might be involved in some complications of pregnancy and/or is an informative pathological marker. First, the G*0106 allele is coupled with presence of the 14-bp sequence in the 3 0 -UTR of the HLA-G gene, which also was associated with PE in the present study. Interestingly, the HLA-G allele containing the 14-bp sequence has been found to be associated with lower HLA-G mRNA levels [46, 87] . Moreover, we demonstrated that alternative forms of HLA-G transcripts, having a deletion of 92 bp (including the 14-bp sequence), are more stable than the complete HLA-G transcripts. These properties might explain a deficit in HLA-G expression associated with some diseases of pregnancy. Second, the G*0106 allele has a nonconservative amino acid substitution in exon 4 (alpha3 extracellular domain) at codon 258 (Thr ! Met). It does not seem very likely that the amino acid substitution changes the overall conformation of HLA-G or influences the contact with CD8, but an effect on the interaction of HLA-G with natural killer receptors and suppression of CD4þ T cells can be considered.
